Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and safety, with no severe side effects. Wave anticipates trial completion in Q1 2025. read more